Last reviewed · How we verify
High dose of Micardis®, once daily — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
High dose of Micardis®, once daily (High dose of Micardis®, once daily) — Boehringer Ingelheim.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| High dose of Micardis®, once daily TARGET | High dose of Micardis®, once daily | Boehringer Ingelheim | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- High dose of Micardis®, once daily CI watch — RSS
- High dose of Micardis®, once daily CI watch — Atom
- High dose of Micardis®, once daily CI watch — JSON
- High dose of Micardis®, once daily alone — RSS
Cite this brief
Drug Landscape (2026). High dose of Micardis®, once daily — Competitive Intelligence Brief. https://druglandscape.com/ci/high-dose-of-micardis-once-daily. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab